Tag: EPI-7386

mCRPC

Johnson & Johnson suspends clinical study of EPI-7386 due to difficulty in patient recruitment

ADC评论 November 1, 2022

On October 31, ESSA Pharma announced that Johnson & Johnson/Janssen Pharmaceuticals will discontinue a Phase I combination therapy clinical study of its lead candidate, EPI-7386,

EPI-7386

ESSA’s mCRPC drug EPI-7386 has positive clinical effects, stock prices soar

ADC评论 October 28, 2022

On October 26, ESSA Pharma announced the latest positive results from the first two cohorts of the company’s lead drug candidate EPI-7386 in combination with

Latest Articles

azide peg linker click chemistry

Leveraging Azide PEG in Biopharmaceuticals: Uniting Azide Linkers and Click Chemistry

October 20, 2023

peg-tco

TCO-Functionalized PEG Derivatives: Versatile Tools for Bioconjugation

October 16, 2023

Tetrazine PEG

Tetrazine and Methyltetrazine: Structural Distinctions and Their Roles in Pharmaceutical Research

October 8, 2023

endo bcn, exo bcn, bcn peg

BCN Compounds in Pharmaceutical Research and Development

October 6, 2023

cydyes

An Overview of Cyanine Dyes: Types, Wavelengths, and Applications Across Industries

September 19, 2023

Protein Conjugation

Unveiling the Power of Protein Conjugation: The Biochemical Game Changer

May 26, 2023

Hot Articles